Glenmark Pharma: Approval for Covid-19 Oral Drug
In Unlock 1 Ill-Effects: Boon for the Consumer Discretionary? we highlighted the current covid 19 scenario where there is not a single trace of...
269 Views
Asia HY Monthly - Takeaways From China's Two Sessions (2020) - Lucror Analytics
From an investor’s perspective, the month of May was dominated by two issues: the likely rate of the post-pandemic economic recovery, and mounting...
329 Views
Asia HY Trade Recommendations - May 2020 - Lucror Analytics
The Asia HY Trade Recommendations report for the month of May includes a summary of our recommendations. The report also features relative-value...
285 Views
Thomson Medical Group: Medicated by Leverage
We initiate our coverage of Thomson Medical Group Limited (ROWS SP) (TMG). The acquisition of a profitable Thomson Medical Centre (TMC) together...
331 Views
Asia HY Monthly - Impact Of COVID-19 On Investment Strategy - Lucror Analytics
The global economic impact of COVID-19 deepened in April, with many countries now expected to see GDP contract in 2020. That said, credit and...
288 Views